Room temperature stable oral calcitonin formulation
Room-temperature stable dosage forms for oral delivery of calcitonin are disclosed herein. Dosage forms for oral delivery of calcitonin with low water content are also disclosed herein. Further disclosed herein are methods for producing such room-temperature stable dosage forms and low-water content dosage forms. Methods of treatment comprising the administration of such room-temperature stable dosage forms and low-water content dosage forms are also disclosed herein.
1. A pharmaceutical solid dosage form for oral delivery of calcitonin comprising:
(a) a calcitonin intermixed with coated acid particles, wherein the coated acid particles are coated with a pharmaceutically acceptable protective coating, wherein the protective coating separates the acid from the calcitonin in the composition;
(b) an enteric coating; and
(c) a water-soluble barrier layer that separates the calcitonin intermixed with coated acid particles from the enteric coating, wherein the solid dosage form contains no more than 2.5% (w/w) water.
2. The pharmaceutical solid dosage form according to claim 1 , wherein the solid dosage form is a capsule or a tablet.
3. The pharmaceutical solid dosage form according to claim 2 , wherein the capsule is a powder-filled capsule.
4. The pharmaceutical solid dosage form according to claim 2 , wherein the capsule is used for over-encapsulation of a tablet core.
5. The pharmaceutical solid dosage form according to claim 2 , wherein the barrier layer is the capsule body and cap.
6. The pharmaceutical solid dosage form according to claim 5 , wherein the capsule body and cap are coated with an enteric coating.
7. The pharmaceutical solid dosage form according to claim 5 , wherein the capsule body and cap comprise one or more pharmaceutically approved enteric polymers.
8. The pharmaceutical solid dosage form according to claim 2 , wherein the solid dosage form is a tablet, wherein the calcitonin intermixed with coated acid particles are present in the tablet core, and wherein the tablet core is coated with the water-soluble barrier layer and the enteric coating.
9. The pharmaceutical solid dosage form according to claim 1 , wherein the solid dosage form contains no more than 2.25% (w/w) water.
10. The pharmaceutical solid dosage form according to claim 1 , wherein the solid dosage form contains no more than 2.0% (w/w) water.
11. The pharmaceutical solid dosage form according to claim 1 , wherein the solid dosage form contains no more than 1.9% (w/w) water.
12. The pharmaceutical solid dosage form according to claim 1 , wherein the solid dosage form contains no more than 1.8% (w/w) water.
13. The pharmaceutical solid dosage form according to claim 1 , wherein the solid dosage form contains no more than 1.7% (w/w) water.
14. The pharmaceutical solid dosage form according to claim 1 , wherein the solid dosage form contains no more than 1.6% (w/w) water.
15. The pharmaceutical solid dosage form according to claim 1 , wherein the solid dosage form contains no more than 1.5% (w/w) water.
16. The pharmaceutical solid dosage form according to claim 1 , wherein total acid in said pharmaceutical solid dosage form is in a quantity which, if added to ten milliliters of 0.1 M aqueous sodium bicarbonate solution, would be sufficient to lower the pH of said solution to no higher than 5.5.
17. The pharmaceutical solid dosage form according to claim 1 , wherein the solid dosage form does not include an amount of base which, if released together with the acid, would prevent the pH of said solution from dropping to 5.5 or below.
18. The pharmaceutical solid dosage form according to claim 1 , wherein the acid is selected from citric acid, tartaric acid and an acid salt of an amino acid.
19. The pharmaceutical solid dosage form according to claim 18 , wherein the acid is citric acid.
20. The pharmaceutical solid dosage form according to claim 1 , wherein the protective coating of the coated acid particles is a sugar.
21. The pharmaceutical solid dosage form according to claim 20 , wherein the sugar is glucose.
22. The pharmaceutical solid dosage form according to claim 20 , wherein the sugar is maltodextrin.
23. The pharmaceutical solid dosage form according to claim 1 , wherein the solid dosage form is a tablet, and wherein the barrier layer is a water-soluble barrier layer.
24. The pharmaceutical solid dosage form according to claim 1 , wherein the solid dosage form is a tablet, and wherein the water-soluble barrier layer is prepared and applied using a non-aqueous solvent.
25. The pharmaceutical solid dosage form according to claim 23 , wherein the water-soluble barrier layer comprises a polyvinyl alcohol-polyethylene glycol graft copolymer.
26. The pharmaceutical solid dosage form according to claim 23 , wherein the solid dosage form is a tablet, and wherein the water-soluble barrier layer adds 3-6% to the weight of the pharmaceutical tablet, exclusive of the enteric coating.
27. The pharmaceutical solid dosage form according to claim 1 , wherein the enteric coating comprises a methacrylic acid-ethyl acrylate copolymer (1:1).
28. The pharmaceutical solid dosage form according to claim 1 , wherein the solid dosage form is a tablet, and wherein the enteric coating adds 6-8% to the weight of the tablet, including the tablet core and the water-soluble barrier layer.
29. The pharmaceutical solid dosage form according to claim 1 , wherein the calcitonin is selected from the group consisting of human calcitonin, salmon calcitonin, eel calcitonin, elkatonin, porcine calcitonin, and chicken calcitonin.
30. The pharmaceutical solid dosage form according to claim 29 , wherein the calcitonin is salmon calcitonin.
31. The pharmaceutical solid dosage form according to claim 30 , wherein the solid dosage form comprises about 100 to about 1000 μg salmon calcitonin.
32. The pharmaceutical solid dosage form according to claim 31 , wherein the solid dosage form comprises about 200 μg salmon calcitonin.
33. The pharmaceutical solid dosage form according to claim 1 , wherein the solid dosage form further comprises an absorption enhancer.
34. The pharmaceutical solid dosage form according to claim 33 , wherein the absorption enhancer is L-lauroyl carnitine.
35. A pharmaceutical tablet for oral delivery of calcitonin comprising:
(a) a tablet core comprising
a. salmon calcitonin intermixed with maltodextrin-coated citric acid particles, wherein the maltodextrin separates the acid from the salmon calcitonin in the composition;
b. crospovidone;
c. copovidone;
d. microcrystalline cellulose; and
e. magnesium stearate;
(b) an enteric coating, wherein the enteric coating comprises a methacrylic acid-ethyl acrylate copolymer (1:1); and
(c) a water-soluble barrier layer that separates the tablet core from the enteric coating, wherein the water-soluble barrier layer comprises a polyvinyl alcohol-polyethylene glycol graft copolymer;
wherein the tablet contains no more than 2.5% (w/w) water.
36. The pharmaceutical tablet according to claim 35 , wherein the tablet comprises about 100 μg to about 1,000 μg salmon calcitonin.
37. The pharmaceutical tablet according to claim 35 , wherein the tablet core comprises
(a) about 0.01% (w/w) to about 0.10% (w/w) salmon calcitonin;
(b) about 62% (w/w) maltodextrin-coated citric acid;
(c) about 1.1% (w/w) crospovidone;
(d) about 5% (w/w) copovidone;
(e) about 31% (w/w) silicified microcrystalline cellulose; and
(f) about 0.5% (w/w) magnesium stearate.
38. The pharmaceutical tablet according to claim 35 , wherein the tablet comprises about 200 μg salmon calcitonin.
39. The pharmaceutical tablet according to claim 35 , wherein the tablet core comprises about 0.02% (w/w) salmon calcitonin.
40. The pharmaceutical tablet according to claim 35 , wherein the water-soluble barrier layer adds about 6% to the weight of the tablet core, exclusive of the enteric coating.
41. The pharmaceutical tablet according to claim 35 , wherein the enteric coating adds about 7% to the weight of the tablet, including the tablet core and the water-soluble barrier layer.
42. A method for treating a bone-related disease, a calcium disorder, an inflammatory disease or a degenerative disease by administering the solid oral dosage form according to claim 1 to a subject in need thereof.
43. The method according to claim 42 , wherein the subject is a mammal.
44. The method according to claim 42 , wherein the subject is a human patient.
45. The method according to claim 42 , wherein bone-related disease is selected from the group consisting of osteoporosis, Paget's disease, pain associated with recent vertebral fragility fracture, and hypercalcemia of malignancy.
46. The method according to claim 42 , wherein the inflammatory disease is selected from the group consisting of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), and ankylosing spondylitis (AS).
47. A method for treating a bone-related disease, a calcium disorder, an inflammatory disease or a degenerative disease by administering the tablet according to claim 35 to a subject in need thereof.
48. The method according to claim 47 , wherein the subject is a human patient.
49. The method according to claim 47 , wherein bone-related disease is selected from the group consisting of osteoporosis, Paget's disease, pain associated with recent vertebral fragility fracture, and hypercalcemia of malignancy.
50. The method according to claim 47 , wherein the inflammatory disease is selected from the group consisting of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), and ankylosing spondylitis (AS).